PubMed:10089214 / 1215-1536 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T7","span":{"begin":0,"end":321},"obj":"Sentence"},{"id":"T7","span":{"begin":0,"end":321},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T29","span":{"begin":73,"end":83},"obj":"FMAID:167180"},{"id":"_T30","span":{"begin":108,"end":118},"obj":"FMAID:167180"},{"id":"_T31","span":{"begin":149,"end":159},"obj":"FMAID:179289"},{"id":"_T32","span":{"begin":149,"end":159},"obj":"FMAID:74552"},{"id":"_T33","span":{"begin":149,"end":159},"obj":"FMAID:222825"},{"id":"_T34","span":{"begin":149,"end":167},"obj":"FMAID:201651"},{"id":"_T35","span":{"begin":149,"end":167},"obj":"FMAID:86697"},{"id":"_T36","span":{"begin":162,"end":167},"obj":"FMAID:169002"},{"id":"_T37","span":{"begin":162,"end":167},"obj":"FMAID:68646"},{"id":"_T38","span":{"begin":206,"end":211},"obj":"FMAID:68646"},{"id":"_T39","span":{"begin":206,"end":211},"obj":"FMAID:169002"},{"id":"_T40","span":{"begin":251,"end":263},"obj":"FMAID:74531"},{"id":"_T41","span":{"begin":251,"end":263},"obj":"FMAID:179268"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"uniprot-human","denotations":[{"id":"T3","span":{"begin":276,"end":279},"obj":"http://www.uniprot.org/uniprot/O75355"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T7","span":{"begin":162,"end":167},"obj":"http://purl.bioontology.org/ontology/STY/T025"},{"id":"T8","span":{"begin":206,"end":211},"obj":"http://purl.bioontology.org/ontology/STY/T025"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GO-BP","denotations":[{"id":"T6","span":{"begin":49,"end":57},"obj":"http://purl.obolibrary.org/obo/GO_0007349"},{"id":"T7","span":{"begin":149,"end":167},"obj":"http://purl.obolibrary.org/obo/GO_0002454"},{"id":"T8","span":{"begin":149,"end":167},"obj":"http://purl.obolibrary.org/obo/GO_0002453"},{"id":"T9","span":{"begin":149,"end":167},"obj":"http://purl.obolibrary.org/obo/GO_0002343"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GO-MF","denotations":[{"id":"T3","span":{"begin":73,"end":83},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T4","span":{"begin":108,"end":118},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T7","span":{"begin":58,"end":65},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T11","span":{"begin":58,"end":65},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T15","span":{"begin":58,"end":65},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T19","span":{"begin":58,"end":65},"obj":"http://purl.obolibrary.org/obo/GO_0005488"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GO-CC","denotations":[{"id":"T5","span":{"begin":162,"end":167},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T6","span":{"begin":206,"end":211},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"EDAM-topics","denotations":[{"id":"T6","span":{"begin":128,"end":133},"obj":"http://edamontology.org/topic_2815"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"EDAM-DFO","denotations":[{"id":"T3","span":{"begin":29,"end":39},"obj":"http://edamontology.org/operation_3465"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GlyCosmos600-FMA","denotations":[{"id":"T10","span":{"begin":162,"end":167},"obj":"Body_part"},{"id":"T11","span":{"begin":206,"end":211},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GlyCosmos600-CLO","denotations":[{"id":"T5","span":{"begin":134,"end":139},"obj":"http://purl.obolibrary.org/obo/CLO_0053432"},{"id":"T6","span":{"begin":160,"end":167},"obj":"http://purl.obolibrary.org/obo/CL_0000236"},{"id":"T7","span":{"begin":191,"end":194},"obj":"http://purl.obolibrary.org/obo/CLO_0053434"},{"id":"T8","span":{"begin":191,"end":194},"obj":"http://purl.obolibrary.org/obo/CLO_0052882"},{"id":"T9","span":{"begin":204,"end":211},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"pubmed-enju-pas","denotations":[{"id":"EnjuParser_T220","span":{"begin":0,"end":5},"obj":"DT"},{"id":"EnjuParser_T221","span":{"begin":6,"end":19},"obj":"NNS"},{"id":"EnjuParser_T222","span":{"begin":20,"end":25},"obj":"MD"},{"id":"EnjuParser_T223","span":{"begin":26,"end":28},"obj":"VB"},{"id":"EnjuParser_T224","span":{"begin":29,"end":39},"obj":"VBN"},{"id":"EnjuParser_T225","span":{"begin":40,"end":44},"obj":"IN"},{"id":"EnjuParser_T226","span":{"begin":45,"end":48},"obj":"DT"},{"id":"EnjuParser_T227","span":{"begin":49,"end":57},"obj":"JJ"},{"id":"EnjuParser_T228","span":{"begin":58,"end":65},"obj":"NN"},{"id":"EnjuParser_T229","span":{"begin":66,"end":68},"obj":"IN"},{"id":"EnjuParser_T230","span":{"begin":69,"end":72},"obj":"DT"},{"id":"EnjuParser_T231","span":{"begin":73,"end":83},"obj":"NNS"},{"id":"EnjuParser_T232","span":{"begin":84,"end":86},"obj":"IN"},{"id":"EnjuParser_T233","span":{"begin":87,"end":94},"obj":"VBZ"},{"id":"EnjuParser_T234","span":{"begin":94,"end":95},"obj":"-COLON-"},{"id":"EnjuParser_T235","span":{"begin":96,"end":103},"obj":"IN"},{"id":"EnjuParser_T236","span":{"begin":104,"end":107},"obj":"DT"},{"id":"EnjuParser_T237","span":{"begin":108,"end":118},"obj":"NNS"},{"id":"EnjuParser_T238","span":{"begin":119,"end":124},"obj":"VBN"},{"id":"EnjuParser_T239","span":{"begin":125,"end":127},"obj":"TO"},{"id":"EnjuParser_T240","span":{"begin":128,"end":133},"obj":"JJ"},{"id":"EnjuParser_T241","span":{"begin":134,"end":136},"obj":"NN"},{"id":"EnjuParser_T242","span":{"begin":137,"end":139},"obj":"CD"},{"id":"EnjuParser_T243","span":{"begin":140,"end":148},"obj":"JJ"},{"id":"EnjuParser_T244","span":{"begin":149,"end":159},"obj":"JJ"},{"id":"EnjuParser_T245","span":{"begin":160,"end":161},"obj":"NN"},{"id":"EnjuParser_T246","span":{"begin":162,"end":167},"obj":"NNS"},{"id":"EnjuParser_T247","span":{"begin":167,"end":168},"obj":"-COMMA-"},{"id":"EnjuParser_T248","span":{"begin":169,"end":174},"obj":"PRP-DOLLAR-"},{"id":"EnjuParser_T249","span":{"begin":175,"end":185},"obj":"NN"},{"id":"EnjuParser_T250","span":{"begin":186,"end":190},"obj":"IN"},{"id":"EnjuParser_T251","span":{"begin":191,"end":194},"obj":"NN"},{"id":"EnjuParser_T252","span":{"begin":195,"end":203},"obj":"JJ"},{"id":"EnjuParser_T253","span":{"begin":204,"end":205},"obj":"NN"},{"id":"EnjuParser_T254","span":{"begin":206,"end":211},"obj":"NNS"},{"id":"EnjuParser_T255","span":{"begin":212,"end":215},"obj":"VBD"},{"id":"EnjuParser_T256","span":{"begin":216,"end":222},"obj":"CC"},{"id":"EnjuParser_T257","span":{"begin":223,"end":229},"obj":"RB"},{"id":"EnjuParser_T258","span":{"begin":230,"end":237},"obj":"VBG"},{"id":"EnjuParser_T259","span":{"begin":238,"end":239},"obj":"-LRB-"},{"id":"EnjuParser_T260","span":{"begin":239,"end":243},"obj":"NN"},{"id":"EnjuParser_T261","span":{"begin":243,"end":244},"obj":"-COMMA-"},{"id":"EnjuParser_T262","span":{"begin":245,"end":248},"obj":"NN"},{"id":"EnjuParser_T263","span":{"begin":248,"end":249},"obj":"-RRB-"},{"id":"EnjuParser_T264","span":{"begin":249,"end":250},"obj":"-COMMA-"},{"id":"EnjuParser_T265","span":{"begin":251,"end":263},"obj":"NN"},{"id":"EnjuParser_T266","span":{"begin":264,"end":265},"obj":"-LRB-"},{"id":"EnjuParser_T267","span":{"begin":265,"end":270},"obj":"RB"},{"id":"EnjuParser_T268","span":{"begin":271,"end":273},"obj":"CD"},{"id":"EnjuParser_T269","span":{"begin":273,"end":274},"obj":"NN"},{"id":"EnjuParser_T270","span":{"begin":274,"end":275},"obj":"-COLON-"},{"id":"EnjuParser_T271","span":{"begin":276,"end":279},"obj":"NN"},{"id":"EnjuParser_T272","span":{"begin":279,"end":280},"obj":"-COMMA-"},{"id":"EnjuParser_T273","span":{"begin":281,"end":285},"obj":"NN"},{"id":"EnjuParser_T274","span":{"begin":285,"end":286},"obj":"-RRB-"},{"id":"EnjuParser_T275","span":{"begin":287,"end":289},"obj":"CC"},{"id":"EnjuParser_T276","span":{"begin":290,"end":298},"obj":"RB"},{"id":"EnjuParser_T277","span":{"begin":299,"end":307},"obj":"JJ"},{"id":"EnjuParser_T278","span":{"begin":308,"end":309},"obj":"-LRB-"},{"id":"EnjuParser_T279","span":{"begin":309,"end":314},"obj":"NN"},{"id":"EnjuParser_T280","span":{"begin":314,"end":315},"obj":"-COMMA-"},{"id":"EnjuParser_T281","span":{"begin":316,"end":318},"obj":"CD"},{"id":"EnjuParser_T282","span":{"begin":318,"end":319},"obj":"NN"},{"id":"EnjuParser_T283","span":{"begin":319,"end":320},"obj":"-RRB-"}],"relations":[{"id":"EnjuParser_R222","pred":"arg1Of","subj":"EnjuParser_T221","obj":"EnjuParser_T220"},{"id":"EnjuParser_R223","pred":"arg1Of","subj":"EnjuParser_T221","obj":"EnjuParser_T222"},{"id":"EnjuParser_R224","pred":"arg2Of","subj":"EnjuParser_T224","obj":"EnjuParser_T222"},{"id":"EnjuParser_R225","pred":"arg1Of","subj":"EnjuParser_T221","obj":"EnjuParser_T223"},{"id":"EnjuParser_R226","pred":"arg2Of","subj":"EnjuParser_T224","obj":"EnjuParser_T223"},{"id":"EnjuParser_R227","pred":"arg2Of","subj":"EnjuParser_T221","obj":"EnjuParser_T224"},{"id":"EnjuParser_R228","pred":"arg1Of","subj":"EnjuParser_T224","obj":"EnjuParser_T225"},{"id":"EnjuParser_R229","pred":"arg2Of","subj":"EnjuParser_T228","obj":"EnjuParser_T225"},{"id":"EnjuParser_R230","pred":"arg1Of","subj":"EnjuParser_T228","obj":"EnjuParser_T226"},{"id":"EnjuParser_R231","pred":"arg1Of","subj":"EnjuParser_T228","obj":"EnjuParser_T227"},{"id":"EnjuParser_R232","pred":"arg1Of","subj":"EnjuParser_T228","obj":"EnjuParser_T229"},{"id":"EnjuParser_R233","pred":"arg2Of","subj":"EnjuParser_T231","obj":"EnjuParser_T229"},{"id":"EnjuParser_R234","pred":"arg1Of","subj":"EnjuParser_T231","obj":"EnjuParser_T230"},{"id":"EnjuParser_R235","pred":"arg1Of","subj":"EnjuParser_T231","obj":"EnjuParser_T232"},{"id":"EnjuParser_R236","pred":"arg2Of","subj":"EnjuParser_T233","obj":"EnjuParser_T232"},{"id":"EnjuParser_R237","pred":"arg1Of","subj":"EnjuParser_T224","obj":"EnjuParser_T234"},{"id":"EnjuParser_R238","pred":"arg1Of","subj":"EnjuParser_T224","obj":"EnjuParser_T235"},{"id":"EnjuParser_R239","pred":"arg2Of","subj":"EnjuParser_T255","obj":"EnjuParser_T235"},{"id":"EnjuParser_R240","pred":"arg1Of","subj":"EnjuParser_T237","obj":"EnjuParser_T236"},{"id":"EnjuParser_R241","pred":"arg2Of","subj":"EnjuParser_T237","obj":"EnjuParser_T238"},{"id":"EnjuParser_R242","pred":"arg1Of","subj":"EnjuParser_T238","obj":"EnjuParser_T239"},{"id":"EnjuParser_R243","pred":"arg2Of","subj":"EnjuParser_T246","obj":"EnjuParser_T239"},{"id":"EnjuParser_R244","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T240"},{"id":"EnjuParser_R245","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T241"},{"id":"EnjuParser_R246","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T242"},{"id":"EnjuParser_R247","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T243"},{"id":"EnjuParser_R248","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T244"},{"id":"EnjuParser_R249","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T245"},{"id":"EnjuParser_R250","pred":"arg1Of","subj":"EnjuParser_T255","obj":"EnjuParser_T247"},{"id":"EnjuParser_R251","pred":"arg1Of","subj":"EnjuParser_T249","obj":"EnjuParser_T248"},{"id":"EnjuParser_R252","pred":"arg1Of","subj":"EnjuParser_T249","obj":"EnjuParser_T250"},{"id":"EnjuParser_R253","pred":"arg2Of","subj":"EnjuParser_T254","obj":"EnjuParser_T250"},{"id":"EnjuParser_R254","pred":"arg1Of","subj":"EnjuParser_T254","obj":"EnjuParser_T251"},{"id":"EnjuParser_R255","pred":"arg1Of","subj":"EnjuParser_T254","obj":"EnjuParser_T252"},{"id":"EnjuParser_R256","pred":"arg1Of","subj":"EnjuParser_T254","obj":"EnjuParser_T253"},{"id":"EnjuParser_R257","pred":"arg1Of","subj":"EnjuParser_T249","obj":"EnjuParser_T255"},{"id":"EnjuParser_R258","pred":"arg2Of","subj":"EnjuParser_T264","obj":"EnjuParser_T255"},{"id":"EnjuParser_R259","pred":"arg1Of","subj":"EnjuParser_T255","obj":"EnjuParser_T256"},{"id":"EnjuParser_R260","pred":"arg2Of","subj":"EnjuParser_T237","obj":"EnjuParser_T256"},{"id":"EnjuParser_R261","pred":"arg1Of","subj":"EnjuParser_T258","obj":"EnjuParser_T257"},{"id":"EnjuParser_R262","pred":"arg1Of","subj":"EnjuParser_T258","obj":"EnjuParser_T259"},{"id":"EnjuParser_R263","pred":"arg2Of","subj":"EnjuParser_T260","obj":"EnjuParser_T259"},{"id":"EnjuParser_R264","pred":"arg3Of","subj":"EnjuParser_T263","obj":"EnjuParser_T259"},{"id":"EnjuParser_R265","pred":"arg1Of","subj":"EnjuParser_T260","obj":"EnjuParser_T261"},{"id":"EnjuParser_R266","pred":"arg2Of","subj":"EnjuParser_T262","obj":"EnjuParser_T261"},{"id":"EnjuParser_R267","pred":"arg1Of","subj":"EnjuParser_T258","obj":"EnjuParser_T264"},{"id":"EnjuParser_R268","pred":"arg2Of","subj":"EnjuParser_T275","obj":"EnjuParser_T264"},{"id":"EnjuParser_R269","pred":"arg1Of","subj":"EnjuParser_T265","obj":"EnjuParser_T266"},{"id":"EnjuParser_R270","pred":"arg2Of","subj":"EnjuParser_T269","obj":"EnjuParser_T266"},{"id":"EnjuParser_R271","pred":"arg3Of","subj":"EnjuParser_T274","obj":"EnjuParser_T266"},{"id":"EnjuParser_R272","pred":"arg1Of","subj":"EnjuParser_T268","obj":"EnjuParser_T267"},{"id":"EnjuParser_R273","pred":"arg1Of","subj":"EnjuParser_T269","obj":"EnjuParser_T268"},{"id":"EnjuParser_R274","pred":"arg1Of","subj":"EnjuParser_T269","obj":"EnjuParser_T270"},{"id":"EnjuParser_R275","pred":"arg2Of","subj":"EnjuParser_T271","obj":"EnjuParser_T270"},{"id":"EnjuParser_R276","pred":"arg1Of","subj":"EnjuParser_T271","obj":"EnjuParser_T272"},{"id":"EnjuParser_R277","pred":"arg2Of","subj":"EnjuParser_T273","obj":"EnjuParser_T272"},{"id":"EnjuParser_R278","pred":"arg1Of","subj":"EnjuParser_T265","obj":"EnjuParser_T275"},{"id":"EnjuParser_R279","pred":"arg2Of","subj":"EnjuParser_T279","obj":"EnjuParser_T275"},{"id":"EnjuParser_R280","pred":"arg1Of","subj":"EnjuParser_T277","obj":"EnjuParser_T276"},{"id":"EnjuParser_R281","pred":"arg1Of","subj":"EnjuParser_T279","obj":"EnjuParser_T277"},{"id":"EnjuParser_R282","pred":"arg2Of","subj":"EnjuParser_T279","obj":"EnjuParser_T278"},{"id":"EnjuParser_R283","pred":"arg3Of","subj":"EnjuParser_T283","obj":"EnjuParser_T278"},{"id":"EnjuParser_R284","pred":"arg1Of","subj":"EnjuParser_T279","obj":"EnjuParser_T280"},{"id":"EnjuParser_R285","pred":"arg2Of","subj":"EnjuParser_T282","obj":"EnjuParser_T280"},{"id":"EnjuParser_R286","pred":"arg1Of","subj":"EnjuParser_T282","obj":"EnjuParser_T281"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G41652MJ\""},{"id":"GlycanIUPAC_T2","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G20761YC\""},{"id":"GlycanIUPAC_T3","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G19807HM\""},{"id":"GlycanIUPAC_T4","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G20351TE\""},{"id":"GlycanIUPAC_T5","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G71957MR\""},{"id":"GlycanIUPAC_T6","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G59040AE\""},{"id":"GlycanIUPAC_T7","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G14987PW\""},{"id":"GlycanIUPAC_T8","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G95064PC\""},{"id":"GlycanIUPAC_T9","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G39143AQ\""},{"id":"GlycanIUPAC_T10","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G65149OO\""},{"id":"GlycanIUPAC_T11","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G02766SY\""},{"id":"GlycanIUPAC_T12","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G26019KJ\""},{"id":"GlycanIUPAC_T13","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G36429CZ\""},{"id":"GlycanIUPAC_T14","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G89633TP\""},{"id":"GlycanIUPAC_T15","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G28494FO\""},{"id":"GlycanIUPAC_T16","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G06219CP\""},{"id":"GlycanIUPAC_T17","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G44237SM\""},{"id":"GlycanIUPAC_T18","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G57948RL\""},{"id":"GlycanIUPAC_T19","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G64016DN\""},{"id":"GlycanIUPAC_T20","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G14536PC\""},{"id":"GlycanIUPAC_T21","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G14356FW\""},{"id":"GlycanIUPAC_T22","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G34565UO\""},{"id":"GlycanIUPAC_T23","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G67124MW\""},{"id":"GlycanIUPAC_T24","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G71457ZU\""},{"id":"GlycanIUPAC_T25","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G55228VZ\""},{"id":"GlycanIUPAC_T26","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G31034MJ\""},{"id":"GlycanIUPAC_T27","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G25776IP\""},{"id":"GlycanIUPAC_T28","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G64442BV\""},{"id":"GlycanIUPAC_T29","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G57018LE\""},{"id":"GlycanIUPAC_T30","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G61761GX\""},{"id":"GlycanIUPAC_T31","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G76318UX\""},{"id":"GlycanIUPAC_T32","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G61906ER\""},{"id":"GlycanIUPAC_T33","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G68723GR\""},{"id":"GlycanIUPAC_T34","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G19540LE\""},{"id":"GlycanIUPAC_T35","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G74944PO\""},{"id":"GlycanIUPAC_T36","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G89489ZJ\""},{"id":"GlycanIUPAC_T37","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G04434YU\""},{"id":"GlycanIUPAC_T38","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G21450PB\""},{"id":"GlycanIUPAC_T39","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G93629QY\""},{"id":"GlycanIUPAC_T40","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G02603TR\""},{"id":"GlycanIUPAC_T41","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G40280JP\""},{"id":"GlycanIUPAC_T42","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G95259IC\""},{"id":"GlycanIUPAC_T43","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G26900FE\""},{"id":"GlycanIUPAC_T44","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G21346KK\""},{"id":"GlycanIUPAC_T45","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G62509FF\""},{"id":"GlycanIUPAC_T46","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G83932AK\""},{"id":"GlycanIUPAC_T47","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G96978IB\""},{"id":"GlycanIUPAC_T48","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G34275DN\""},{"id":"GlycanIUPAC_T49","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G07071JF\""},{"id":"GlycanIUPAC_T50","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G80639QD\""},{"id":"GlycanIUPAC_T51","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G99460PJ\""},{"id":"GlycanIUPAC_T52","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G22024BZ\""},{"id":"GlycanIUPAC_T53","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G74097ZY\""},{"id":"GlycanIUPAC_T54","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G84439YP\""},{"id":"GlycanIUPAC_T55","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G52207WQ\""},{"id":"GlycanIUPAC_T56","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G90695MS\""},{"id":"GlycanIUPAC_T57","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G50398QX\""},{"id":"GlycanIUPAC_T58","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G12166ZT\""},{"id":"GlycanIUPAC_T59","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G48368BR\""},{"id":"GlycanIUPAC_T60","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G57407RW\""},{"id":"GlycanIUPAC_T61","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G00386TY\""},{"id":"GlycanIUPAC_T62","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G18723JK\""},{"id":"GlycanIUPAC_T63","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G93757OR\""},{"id":"GlycanIUPAC_T64","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G29006SI\""},{"id":"GlycanIUPAC_T65","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G03099OQ\""},{"id":"GlycanIUPAC_T66","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G53739OW\""},{"id":"GlycanIUPAC_T67","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G70440ZO\""},{"id":"GlycanIUPAC_T68","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G29951RR\""},{"id":"GlycanIUPAC_T69","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G58402TI\""},{"id":"GlycanIUPAC_T70","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G39875TP\""},{"id":"GlycanIUPAC_T71","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G83439QV\""},{"id":"GlycanIUPAC_T72","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G41762RC\""},{"id":"GlycanIUPAC_T73","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G91604UI\""},{"id":"GlycanIUPAC_T74","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G88447WE\""},{"id":"GlycanIUPAC_T75","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G93634BS\""},{"id":"GlycanIUPAC_T76","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G02587BH\""},{"id":"GlycanIUPAC_T77","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G43511MX\""},{"id":"GlycanIUPAC_T78","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G64958DH\""},{"id":"GlycanIUPAC_T79","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G30384TR\""},{"id":"GlycanIUPAC_T80","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G15624EX\""},{"id":"GlycanIUPAC_T81","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G22706ST\""},{"id":"GlycanIUPAC_T82","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G57408PI\""},{"id":"GlycanIUPAC_T83","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G86403XX\""},{"id":"GlycanIUPAC_T84","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G78043YB\""},{"id":"GlycanIUPAC_T85","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G18952JK\""},{"id":"GlycanIUPAC_T86","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G49020ND\""},{"id":"GlycanIUPAC_T87","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G63590YW\""},{"id":"GlycanIUPAC_T88","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G22793KS\""},{"id":"GlycanIUPAC_T89","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G64134SS\""},{"id":"GlycanIUPAC_T90","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G17338HY\""},{"id":"GlycanIUPAC_T91","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G99745XF\""},{"id":"GlycanIUPAC_T92","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G27782HN\""},{"id":"GlycanIUPAC_T93","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G57496DC\""},{"id":"GlycanIUPAC_T94","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G93169WB\""},{"id":"GlycanIUPAC_T95","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G05518TD\""},{"id":"GlycanIUPAC_T96","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G62603DN\""},{"id":"GlycanIUPAC_T97","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G59574FS\""},{"id":"GlycanIUPAC_T98","span":{"begin":104,"end":107},"obj":"\"http://rdf.glycoinfo.org/glycan/G47567WC\""}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GlyCosmos15-NCBITAXON","denotations":[{"id":"T3","span":{"begin":128,"end":133},"obj":"OrganismTaxon"}],"attributes":[{"id":"A3","pred":"db_id","subj":"T3","obj":"9606"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GlyCosmos15-CL","denotations":[{"id":"T5","span":{"begin":160,"end":167},"obj":"Cell"},{"id":"T6","span":{"begin":204,"end":211},"obj":"Cell"}],"attributes":[{"id":"A5","pred":"cl_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CL:0000236"},{"id":"A6","pred":"cl_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CL:0000084"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T7","span":{"begin":0,"end":321},"obj":"Sentence"},{"id":"T7","span":{"begin":0,"end":321},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T7","span":{"begin":0,"end":321},"obj":"Sentence"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"NCBITAXON","denotations":[{"id":"T3","span":{"begin":128,"end":133},"obj":"OrganismTaxon"}],"attributes":[{"id":"A3","pred":"db_id","subj":"T3","obj":"9606"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}

{"project":"CL-cell","denotations":[{"id":"T5","span":{"begin":160,"end":167},"obj":"Cell"},{"id":"T6","span":{"begin":204,"end":211},"obj":"Cell"}],"attributes":[{"id":"A5","pred":"cl_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CL:0000236"},{"id":"A6","pred":"cl_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CL:0000084"}],"text":"These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%)."}